KVL-9
KVL‑9 is an intermediate for constructing KRAS-degrading antibody-drug conjugates (DAC), consisting of a KRAS small-molecule binder, a spacer, a VHL-recruiting ligand, and a cleavable antibody linker. By conjugating with tumor antigen-targeting antibodies, KVL‑9 enables antigen-dependent intracellular delivery and induces VHL‑mediated ubiquitin‑proteasome degradation of KRAS protein. KVL‑9 can be used for the synthesis of DACs. KVL‑9 is applicable to cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3113309-33-1
- Formule: C140H192F2N38O34S2
- Masse moléculaire:3053.38
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
KVL-9 achieves antigen-dependent intracellular delivery via conjugation with tumor antigen-targeting antibodies, releases KRAS degrader inside tumor cells, and degrades KRAS protein through the VHL-mediated ubiquitin-proteasome pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 3113309-33-1
-
Masse moléculaire 3053.38
-
Formule C140H192F2N38O34S2
-
SMILES
C[C@@]1(C2=NC(C3=NC(N4[C@H](CN(CCC4)CCCCOC5=CN(N=N5)[C@@H](C(C)C)C(N6[C@@H](C[C@H](C6)O)C(N[C@H](C7=C(C=C(C8=C(C)N=CS8)C(F)=C7)OCC9=CC=C(C=C9)NC([C@H](C)NC([C@H](C)NC(CCC%10=C(C(F)=C(N%11C(C=CC%11=O)=O)C=C%10)OCCCC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)C)=NC=C3)=NO2)C%12=C(CCC1)SC(N)=C%12C#N
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. HY-186226-1.pdf
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)